December 2024 FDA Recall Levothyroxine Sodium by Lupin Pharmaceuticals Inc.
D-0167-2025 - Failed Impurities/Degradation Specifications

This Class II drug recall was voluntarily initiated by Lupin Pharmaceuticals Inc. on December 20, 2024 for the product Levothyroxine Sodium. The FDA reported the reason for recall as failed impurities/degradation specifications. The product was distributed in One US distributor in Ohio. and the recall is currently terminated.

Recall Number: D-0167-2025

Reason for Recall
Failed Impurities/Degradation Specifications: Out of specifications result observed in the drug substance for impurity test during 3-month long term stability study.
Initiated
12-20-2024
Reported
01-08-2025
Quantity
480 1000-count bottles

Recall Profile & Regulatory Data

Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Lupin Pharmaceuticals Inc.
One US distributor in Ohio.
Levothyroxine Sodium Tablets, Lupin, 75 mcg (0.075mg), 1000 Tablets, Rx Only, Manufactured for: Lupin Pharmaceuticals, Inc. Baltimore, Maryland 21202 United States, Manufactured by: Lupin Limited, Pithampur (M.P)- 454 775 INDIA, NDC# 68180-967-03

Batch or Lot Expiration Information

Lot# LA01276, Exp Date: 07/2026

Affected Packages Involved in this Recall